CoChat

Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands

Open access

The DOI matches its Crossref record; 49 of the 52 references it cites were found in a registry or an index.

Abstract

Hormone-dependent cancers, such as certain types of breast cancer are characterized by over-expression of estrogen receptors (ERs). Anticancer drug conjugates combining ER ligands with other classes of anticancer agents may not only benefit from dual action at both anti-cancer targets but also from selective delivery of cytotoxic agents to ER-positive tumor cells resulting in less toxicity and adverse effects. Moreover, they could also take advantage of overcoming resistance typical for anti-hormonal monotherapy such as tamoxifen. In this review, we discuss the design, structures and pharmacological effects of numerous series of drug conjugates containing ER ligands such as selective ER modulators (tamoxifen, 4-hydroxytamoxifen, endoxifen), selective ER degraders (ICI-164384) and ER agonists (estradiol) linked to diverse anti-cancer agents including histone-deacetylase inhibitors, DNA-alkylating agents, antimitotic agents and epidermal growth factor receptor inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics15010067

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Structures of estrogen receptor ligands and estramustine phosphate.
Figure 1 Structures of estrogen receptor ligands and estramustine phosphate.CC BY · PubMed Central
Figure 2 Structures of selected drug conjugates incorporating tamoxifen.
Figure 2 Structures of selected drug conjugates incorporating tamoxifen.CC BY · PubMed Central
Figure 3 Crystal structure of 4-hydroxytamoxifen bound to ERα (PDB 3ERT). The dimethylamino group is solvent exposed allowing for attaching the linker without substantial disruption of binding.
Figure 3 Crystal structure of 4-hydroxytamoxifen bound to ERα (PDB 3ERT). The dimethylamino group is solvent exposed allowing for attaching the linker without substantial disruption of binding.CC BY · PubMed Central
Figure 4 Structures of selected drug conjugates incorporating 4-hydroxytamoxifen.
Figure 4 Structures of selected drug conjugates incorporating 4-hydroxytamoxifen.CC BY · PubMed Central
Figure 5 Structures of selected drug conjugates incorporating steroids.
Figure 5 Structures of selected drug conjugates incorporating steroids.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. (2022, December 22). Available online: https://pubmed.ncbi.nlm.nih.gov/?term=anticancer+hybrids.
  2. (2022, December 22). Available online: https://adisinsight.springer.com/drugs/800028795.

Cited by

See all 10

Metadata

Authors
Zlotos, D. P., Kronenberger, T., & Laufer, S. A.
Affiliations
  • German University in Cairo (EG)
  • Universitätsklinikum Tübingen (DE)
  • University of Tübingen (DE)
Corresponding author
  • Zlotos, Darius P.
  • Laufer, Stefan A.
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2022-12-26
Volume
15
Issue
1
Pages
67
ISSN
1999-4923 (ISSN-L)
OpenAlex
W4313245134
Cited by
9
References
52
Citations by year
2026: 1 · 2025: 2 · 2024: 5 · 2023: 1
FWCI
0.31
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
German Academic Exchange Service (Sustainable Research Cooperation between GUC and Tuebingen University)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
estrogen receptor ligands, hormone-dependent breast cancer, tamoxifen, endoxifen, 4-hydroxytamoxifen, selective estrogen receptor modulators, selective estrogen receptor degrader, estradiol, histone deacetylase inhibitors, DNA alkylating agents, antimitotic agents, EGFR inhibitors, targeted drug delivery, tamoxifen resistance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.